Search research articles
Contact Us
Filters
Showing results (261-270 of 437) with videos related to
Page
of 44
Sort By:
American Journal of Respiratory and Critical Care Medicine
|
April 2, 2025
Oscillometry-defined Small Airway Dysfunction in Tobacco-exposed Adults with Impaired or Preserved Airflow
Mustafa Abdo, Henrik Watz, Frederik Trinkmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 30, 2009
Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial
Jean-Yves Douillard, Frances A Shepherd, Vera Hirsh, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 17, 2016
The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial
Martin Reck, Mark A Socinski, Alexander Luft, et al.
British Journal of Cancer
|
May 3, 2025
SMAD2 linker phosphorylation impacts overall survival, proliferation, TGFβ1-dependent gene expression and pluripotency-related proteins in NSCLC
Dörte Nitschkowski, Tim Vierbuchen, Holger Heine, et al.
Current Medical Research and Opinion
|
February 10, 2018
Evaluation of changes in renal function in PARAMOUNT: a phase III study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer
Gary Middleton, Cesare Gridelli, Filippo De Marinis, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 29, 2016
An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer
Silvia Novello, Giorgio Scagliotti, Gilberto de Castro, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 23, 2020
Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ)
Yung-Jue Bang, Talia Golan, Laetitia Dahan, et al.
Frontiers in Oncology
|
March 1, 2021
<i>nab</i>-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+)
Daniel Morgensztern, Manuel Cobo Dols, Santiago Ponce Aix, et al.
Molecular Oncology
|
March 9, 2023
Comparative evaluation of PD-L1 expression in cytology imprints, circulating tumour cells and tumour tissue in non-small cell lung cancer patients
Mustafa Abdo, Yassine Belloum, David Heigener, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 26, 2011
Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer
Suresh S Ramalingam, David R Spigel, David Chen, et al.
Page
of 44
Search research articles
Search
Showing results (261-270 of 437) with videos related to
Sort By:
Page
of 44
American Journal of Respiratory and Critical Care Medicine
|
April 2, 2025
Oscillometry-defined Small Airway Dysfunction in Tobacco-exposed Adults with Impaired or Preserved Airflow
Mustafa Abdo, Henrik Watz, Frederik Trinkmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 30, 2009
Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial
Jean-Yves Douillard, Frances A Shepherd, Vera Hirsh, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 17, 2016
The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial
Martin Reck, Mark A Socinski, Alexander Luft, et al.
British Journal of Cancer
|
May 3, 2025
SMAD2 linker phosphorylation impacts overall survival, proliferation, TGFβ1-dependent gene expression and pluripotency-related proteins in NSCLC
Dörte Nitschkowski, Tim Vierbuchen, Holger Heine, et al.
Current Medical Research and Opinion
|
February 10, 2018
Evaluation of changes in renal function in PARAMOUNT: a phase III study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer
Gary Middleton, Cesare Gridelli, Filippo De Marinis, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 29, 2016
An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer
Silvia Novello, Giorgio Scagliotti, Gilberto de Castro, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 23, 2020
Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ)
Yung-Jue Bang, Talia Golan, Laetitia Dahan, et al.
Frontiers in Oncology
|
March 1, 2021
<i>nab</i>-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+)
Daniel Morgensztern, Manuel Cobo Dols, Santiago Ponce Aix, et al.
Molecular Oncology
|
March 9, 2023
Comparative evaluation of PD-L1 expression in cytology imprints, circulating tumour cells and tumour tissue in non-small cell lung cancer patients
Mustafa Abdo, Yassine Belloum, David Heigener, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 26, 2011
Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer
Suresh S Ramalingam, David R Spigel, David Chen, et al.
Page
of 44